Compare Agilysys Inc (AGYS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilysys Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Agilysys Inc trades at $106.06 (market cap $3.02B), while Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 44× Agilysys Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Agilysys Inc nearer its low. Which is the better fit depends on your goals.
| AGYS | VRTX | |
|---|---|---|
Market Cap | $3.02B | $132.79B |
Sector | Technology | Health |
52-Week High | $141.12 | $529.65 |
52-Week Low | $62.19 | $376.62 |
Enterprise Value | $2.92B | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilysys (AGYS) trades at $108.58, up 0.93% with strong bullish momentum supported by recent earnings beats and positive analyst sentiment. The stock shows robust fundamental performance with Q1 2026 EPS of $0.63 beating expectations and record subscription revenue growth. Technical indicators suggest bullish momentum with the current price near pivot point resistance at $108, while moving averages signal continued upward trend potential.
The outlook remains positive with 100% analyst buy ratings and a $118.33 consensus price target representing 9% upside. Key catalysts include continued subscription growth and Marriott deployment progress, though elevated valuation multiples (P/E 70.45) and competitive pressures in hospitality software present risks requiring monitoring of execution consistency.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilysys Inc
Agilysys provides enterprise software and SaaS solutions for the hospitality industry. Its products specialize in point-of-sale, property management, and inventory systems for hotels, resorts, and cruise lines.
Read more on AGYS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
